Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical studies with candesartan.

L Hansson1

  • 1Clinical Hypertension Research, Department of Public Health and Social Sciences, Geriatrics, University of Uppsala, Sweden.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Operations for extrahepatic bile duct cancers: are the results really improving?

The European journal of surgery = Acta chirurgica·2000
Same author

Blood pressure @ Internet-www.bloodpressure.nu.

Blood pressure·2000
Same author

Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics.

Blood pressure·2000
Same author

Endothelial dysfunction--a challenge for hypertension research.

Blood pressure·2000
Same author

Introduction: the role of combination therapy in modern antihypertensive therapy.

Journal of cardiovascular pharmacology·2000
Same author

Changes in glycosylation of human bile-salt-stimulated lipase during lactation.

Archives of biochemistry and biophysics·2000

Candesartan cilexetil, an AT(1)-receptor antagonist, demonstrates excellent tolerability and potent antihypertensive efficacy comparable or superior to other treatments. Ongoing studies are further investigating its clinical impact.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Candesartan cilexetil is an approved AT(1)-receptor antagonist.
  • It is widely used in clinical practice globally.

Purpose of the Study:

  • To summarize clinical studies on candesartan cilexetil.
  • To highlight its tolerability and efficacy.

Main Methods:

  • Review of clinical studies involving candesartan cilexetil.
  • Comparison with placebo and other antihypertensive agents in double-blind trials.

Main Results:

  • Candesartan cilexetil exhibits remarkable tolerability, with a side effect profile similar to placebo.
  • It demonstrates potent antihypertensive efficacy, often superior to established treatments.

Related Experiment Videos

  • Ongoing intervention studies, like SCOPE, are exploring its broader clinical impact.

    • Conclusions:

    • Candesartan cilexetil is a well-tolerated and effective antihypertensive medication.
    • Its potency and safety profile make it a valuable therapeutic option.
    • Further research is evaluating its role in intervention studies.